ckd glp-1 GLP1 Receptor Agonists vs SGLT2-I in Preventing in T2DM: An Interview – AJKD Blog New Medications for Slowing CKD

However, HDL-C may be considered as an additional parameter in cardiovascular risk stratification using the SCORE scale

explored the therapeutic potential of Yisui Tongjing (YSTJ) in treating GuillainBarr Syndrome (GBS), a neuroinflammatory condition with overlapping pathological features observed in AD

Sweating is not listed as a common adverse effect in the official prescribing information for most GLP-1 receptor agonists, and there is no established direct pharmacological mechanism linking these medications to increased perspiration

Data availability The source data supporting the findings of this article are included in this article and its supplementary information files

Gut Hormones and Weight Regulation: The Role of GLP-1 in Obesity Treatment

Animal models show reduced osteoarthritis progression and improved cartilage quality